Gregory K. Pennock, MD



  • 21 years of clinical trial leadership and medical monitoring specializing in oncology and internal medicine.

Clinical Trial Leadership and Management, Medical Monitoring, Medicine (attending physician), and Academia. Specialty: Medical Oncology and Internal Medicine.
Has 23 publications, two grants, and nine invited presentations, internationally. MD, University of TX Medical Branch.
Medical Monitor and Clinical Trial Lead
Providing medical monitoring and clinical trial leadership for a variety of oncology exploratory to Phases 1-3 studies for pharma clients including Bristol-Myers Squibb; Apexigen, Inc.; Hengrui Therapeutics, Inc.; NewLink Genetics Corporation; Tesaro, Inc.; InventisBio, Inc.; and Astex Pharmaceuticals:

  • Phase 1b antibody-drug conjugate for ovarian cancer and non-small cell lung cancer for Boston biotech
  • Phase 1b anti-PD-1 molecule for refractory solid tumors for Boston biotech
  • Phase 1b CD40 agonistic antibody for melanoma, non-small cell lung cancer (2 trials, one single agent; another in combination with checkpoint inhibitor) for Bay area biotech
  • Phase 1 tyrosine kinase inhibitor for HER2-positive refractory solid tumors for Chinese biotech
  • Phase 3 symptom management (antiemetic) for patients receiving highly emetogenic chemotherapy
  • Phase 1 SERD +/- CDK 4/6 inhibitor for metastatic breast cancer
  • Phase 2 PARP inhibitor for non-small cell lung cancer
  • Phase 3 randomized study comparing nivolumab and ipilimumab combination versus placebo in participants with localized renal cell carcinoma who underwent radical or partial nephrectomy and who are at high risk of relapse
  • Exploratory study to investigate the immunomodulatory activity of various dose levels of anti-programmed-death-1 (PD-1) antibody (BMS-936558) in subjects with metastatic clear cell renal cell carcinoma
  • Randomized, blinded, Phase 2, dose-ranging study of BMS-936558 (MDX-1106) in subjects with progressive advanced clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
  • Phase 1 study of nivolumab (BMS-936558) plus sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma
  • Safety and efficacy study of the CD40 agonistic antibody APX005M administered in combination with nivolumab in subjects with non-small cell lung cancer and subjects with metastatic melanoma
  • Two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
  • Phases 2/3 (adaptive design) study of the concomitant administration of indoximod or placebo plus pembrolizumab or nivolumab in adult patients with unresectable stage III or stage IV malignant melanoma
  • Phase 2, multi-arm study of niraparib administered alone and in combination with pembrolizumab in patients with non-small cell lung cancer
  • Study of rolapitant iv in subjects receiving platinum-based chemotherapy after failing fosaprepitant
  • Phase 2, randomized, double blinded, placebo-controlled study of indoximod, durvalumab, gemcitabine, and nab-paclitaxel; or gemcitabine and nab-paclitaxel for patients with chemotherapy-naïve metastatic adenocarcinoma of the pancreas
  • Phase 1 trial of D-0751 in combination with avelumab in advanced or metastatic solid tumors
  • Phase I, open-label study of D-0502 single agent and D-0502 in combination with palbociclib in postmenopausal women with advanced or metastatic ER positive and HER2 negative breast cancer
  • Phase 3, randomized, open-label, crossover study of ASTX727 (cedazuridine and decitabine fixed-dose combination) versus IV decitabine in subjects with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
  • Efficacy and safety study of the CD40 agonistic antibody APX005M administered in immunotherapy-naïve subjects with metastatic melanoma

Principal / Co-Investigator: Division of Hematology/Oncology Baptist/MD Anderson Cancer Center Orlando; Division of Hematology/Oncology, Levine Cancer Institute, Carolinas Healthcare Systems; University of Pittsburgh Cancer Institute

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.